Navigation Links
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors

SAN MATEO, Calif., Oct. 30 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, today announced that Donald J. Santel has been appointed to Anthera's Board of Directors.

"Don's experience in transforming early biotech startups into commercial stage organizations will be of benefit as we expand our pipeline and move A-002 into large scale Phase III clinical trials," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "His strategic and operational insights related to the challenges facing development stage companies will be invaluable as Anthera embarks on the next phase of growth."

"We're pleased to have an individual of Don's caliber join our Board of Directors," said Lowell E. Sears Chairman of Anthera's Board of Directors. "We look forward to his contributions that will further shape strategic direction and drive future growth."

Donald J. Santel has 25 years experience in the biotechnology/biopharmaceutical and medical device industries. Most recently, he was Co-Founder and Chief Executive Officer at CoTherix, Inc., where he launched Ventavis(R) Inhalation Solution and led the sale of the company to Actelion Pharmaceuticals, Ltd. in January 2007. Prior to CoTherix, he served as President and Chief Operating Officer of Reflow, and sold the company to Fox Hollow (now EV3) and served as Vice President of Marketing and International Sales at Cardiac Pathways Corporation, a medical device company later acquired by Boston Scientific. Mr. Santel began his career at Medtronic, Inc. Mr. Santel also serves on the board of Hyperion Therapeutics. He has a BSE from Purdue University and an MS in from the University of Minnesota.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life-threatening chronic and acute inflammatory diseases. In 2006, Anthera acquired worldwide rights (except Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases including: acute chest syndrome, acute lung injury, acute respiratory distress syndrome, atherosclerosis, acute coronary syndrome, chronic obstructive pulmonary disease and psoriasis. In order to efficiently commercialize this platform, Anthera has brought together a proven management team with extensive experience in licensing, clinical research, development, and commercialization of anti-inflammatory products. For more information please visit


Anne Bowdidge

(650) 218-6900

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. McDonalds: French Fries, Transparent to more Trans -Fats
2. French fries by McDonalds fries in another controversy
3. Hospital Withdraws McDonalds Reward Scheme
4. Fat Content In McDonald’s & KFCs Foods Varies From Country To Countr
5. McDonald Sets Aside Promises of Healthy Menu
6. Bird flu no threat to McDonalds chicken: Advertisement strategy
7. Hepatitis Scare at McDonald’
8. McDonalds to Start Coffee Chain in Japan
9. Study casts doubt on keyboard ills
10. Who Board To Discuss Asian Tsunami Related Health Issues
11. Abdominal Crunches Not The Best Option For Wash Board Abs.
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology: